Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform

AORTIC 2025

Published: 27 Jan 2026

Views: 12

Rating:

Save

Dr Chiswili Yves Chabu - University of Missouri, Columbia, USA

Dr Chiswili Yves Chabu speaks to ecancer about immunoprevention and early detection of lung cancer in Africa.

Initially, he talks about the challenges to lung cancer detection and prevention in Africa. He then talks about the LUNG-GUARD platform and its goals and objectives.

He also touches upon why early detection is important and what impact do resource-constraints have in this setting.

Related Videos

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Dr Ryan Nguyen, Rebecca Timogtimog, Carmela Timogtimog

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey ( Dr Ryan Nguyen, Rebecca Timogtimog, Carmela Timogtimog )

I-DXd shows strong brain metastasis responses in extensive-stage small cell...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior...

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR...

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR...

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )

WCLC 2025: Latest in EGFR positive NSCLC

Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil...

WCLC 2025: Latest in EGFR positive NSCLC ( Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

More from ecancer